Foresite Capital, a San Francisco, CA-based multi-stage healthcare and life sciences investment firm, closed its fifth fundraise with $969m in capital commitments.
The offering comprises:
- Foresite Capital Fund V, L.P., and
- Foresite Capital Opportunity Fund V, L.P.
With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages with ~$4 billion in assets under management.
Launched in 2011 and led by CEO Dr. Jim Tananbaum, Foresite Capital is a healthcare and life sciences investment firm, which has spent nearly a decade focused solely on companies within the industry, including 10x Genomics, Element Biosciences, Lyell Immunopharma, Inscripta, Relay Therapeutics, Gemini Therapeutics, and more.
With 27 MDs and PhDs on its team, including managing directors Dr. Michael Rome and adding Alisa Mall, Foresite Capital works closely with the companies it invests in to help guide their products to commercial success.
With Fund V, Foresite Capital plans to invest in companies, spanning all stages, that are focused on therapeutics, life science infrastructure and individualized healthcare. Limited partners in Fund V include a broad range of investors, among them university endowments, public and private pension funds, insurance companies, foundations, corporate investors and prominent individuals and families worldwide.
In October 2019, the firm launched Foresite Labs, an incubator that builds and scales transformative companies at the intersection of data science and healthcare. Run by Dr. Vik Bajaj, the former chief scientific officer of GRAIL and the co-founder and former chief scientific officer of Verily (formerly Google Life Sciences), Foresite Labs aims to solve questions surrounding next-generation therapeutics and healthcare services to ultimately improve patient outcomes and is currently incubating five companies.